BT-001
BT-001 is a multifunctional oncolytic virus
encoding for an anti-CTLA4 antibody and GM-CSF
BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse.
Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune response.
Discover how BT-001 works
Key figures
SITC 2021, Semmrich et al, Poster, see poster
SITC 2020, Semmrich et Al, Poster, see poster
Semmrich et al., Journal for ImmunoTherapy of Cancer 2022;10:e003488. See poster
Collaboration agreement
BioInvent and Transgene are together creating a novel armed oncolytic virus that will be able to infect and selectively replicate within the tumor, inducing cancer cell destruction, and to elicit a strong immune response that is further enhanced by the local expression of the immune checkpoint inhibitor and the cytokine. This novel oncolytic virus is expected to deliver better treatment outcomes with an improved safety profile as the patient is not exposed to the the anti-CTLA4 antibody at a systemic level.
Clinical trials
| Indication | Phase | |
|---|---|---|
| Solid tumors | Phase I/IIa | More information |
- March 9, 2022 - Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
- January 20, 2022 - Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
- November 9, 2021 - Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
- Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
Semmrich M, Marchand J, Fend L, et al
Journal for ImmunoTherapy of Cancer 2022;10:e003488.
doi: 10.1136/jitc-2021-003488
Download the publication here - Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M Marchand J, Rehn M et al.
SITC 2021
Download the poster here
Poster Presentation
